No Data
No Data
Fosun Pharma's New Drug Application Accepted
Express News | Shanghai Fosun Pharma - Unit's Drug Registration Application for Dobutamine Hydrochloride Injection Accepted by Nmpa
The large cap pullback opens the investment window, highlighting the undervalued and scarce symbol of fosun pharma (600196.SH; 02196.HK).
In this round of market trends, the pharmaceutical sector is undoubtedly one of the most obvious offensive assets that have shifted marginally under the influence of the overall market rise. Among them, fosun pharma (600196.SH;02196.HK) as the representative of the "first tier innovative drugs enterprise" has become the high-quality symbol that has been the first to start within this sector.
fosun pharma (600196.SH): The hydrochloride dobutamine injection has been accepted for pharmaceutical registration application.
GeLongHui October 14th | Fosun Pharma (600196.SH) announced that its holding subsidiary Shanghai Chaohui Pharmaceutical Co., Ltd.'s registration application for Dobutamine Hydrochloride Injection was recently accepted by the National Medical Products Administration. This new drug is a chemical drug independently developed by the group, intended for (1) enhancing myocardial contractility in cases of acute circulatory dysfunction, and (2) for observing stress echocardiography.
Shanghai Fosun Pharma Announces Capital Reduction
Shareholder anhui sunhere pharmaceutical excipients (300452.SZ) shareholding fosun pharma accumulatively reduced 2.8263 million shares.
Anhui Sunhere Pharmaceutical Excipients (300452.SZ) announced that shareholder Fosun Pharma acquired from June 15, 2020 to...
No Data
No Data